Team CanUK: Novel antibacterial targets, assays, probes and opportunities in bacterial cell wall biogenesis

CanUK 团队：细菌细胞壁生物发生中的新型抗菌靶点、检测方法、探针和机遇

• 批准号: G1100127/1
• 负责人: Christopher Dowson
• 金额: $ 126.87万
• 依托单位: University of Warwick
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1100127%2F1
• 关键词: Team; CanUK; Novel; antibacterial; targets

Millions of people die each year from bacterial infections and tens of millions suffer from the consequences of these infections. The discovery of the antibiotic penicillin once opened the door to treat these infections by stopping bacteria making the polymer in the cell wall that holds them together. This polymer, called peptidoglycan, is made up of an interlocking network of sugars and strings of amino acids (peptides). Specialised proteins (called PBPs), with the ability to stitch together these sugars and peptides are the targets inhibited by penicillin, stopping cell wall synthesis and killing the bacterium. Many important bacteria are no longer killed by penicillin and other antibiotics that attack other stages in the production of peptidoglycan. Bacteria have changed, evading the action of these antibiotics. We need to fight back. Our progress until recently has been hampered by our inability to routinely synthesise the key chemical components that make this polymer. We can now do this. This is exciting, as we develop the capability to explore important unanswered questions about how bacteria grow and control the production of peptidoglycan. We wish to pull together the expertise of UK and Canadian scientists in a cooperative and coordinated partnership to increase our understanding of the fundamental biology of this process. All of this will open fundamentally new biological insights, and opportunities to use these for the future development of new antibiotics that will work against multiply antibiotic resistant bacteria like MRSA and TB.

每年有数百万人死于细菌感染，数千万人遭受这些感染的后果。抗生素盘尼西林的发现曾经为通过阻止细菌在细胞壁中制造将它们结合在一起的聚合物来治疗这些感染打开了大门。这种聚合物被称为肽聚糖，是由糖和氨基酸链（肽）组成的连锁网络。有能力将这些糖和肽结合在一起的特殊蛋白质（称为PBPs）是青霉素抑制的目标，阻止细胞壁合成并杀死细菌。许多重要的细菌不再被青霉素和其他抗生素杀死，这些抗生素攻击肽聚糖生产的其他阶段。细菌已经发生了变化，避开了这些抗生素的作用。我们需要反击。直到最近，我们的进展一直受到阻碍，因为我们无法常规地合成制造这种聚合物的关键化学成分。我们现在可以这样做。这是令人兴奋的，因为我们有能力探索关于细菌如何生长和控制肽聚糖生产的重要未解问题。我们希望在合作和协调的伙伴关系中汇集英国和加拿大科学家的专业知识，以增加我们对这一过程的基本生物学的理解。所有这些都将从根本上开启新的生物学见解，并为未来开发新的抗生素提供机会，这些抗生素将用于对抗MRSA和结核病等多重抗生素耐药细菌。